Skip to main content
main-content
Top

approvalsWatch: Neurology 280116

US FDA Approvals

Sumatriptan
The FDA has approved sumatriptan nasal powder, formerly known as AVP-825, for the acute treatment of migraine, with or without aura, in adults. The fast-acting dry powder formulation consisting of a low 22 mg dose of sumatriptan is delivered using the Xsail™ Breath Powered Delivery Device.